JIANMIN GROUP(SH:600976) Sou Hu Cai Jing·2025-08-01 10:17Financial Performance - As of August 1, 2025, Jianmin Group's stock closed at 42.66 yuan, up 2.42%, with a turnover rate of 3.42% and a trading volume of 52,400 lots, amounting to 222 million yuan [1] - For Q1 2025, the company reported total revenue of 892 million yuan, a year-on-year decrease of 8.04%, while net profit attributable to shareholders was 110 million yuan, an increase of 10.70% [1] - The company's non-recurring net profit was 103 million yuan, reflecting a year-on-year growth of 13.92% [1] - The liquidity ratios are as follows: current ratio at 1.646, quick ratio at 1.456, and debt-to-asset ratio at 40.15% [1] Capital Flow - On the reporting day, the net inflow of main funds was 21.48 million yuan, accounting for 9.69% of the total transaction amount [1] - Large orders saw a net inflow of 15.24 million yuan, representing 6.88% of the transaction amount, while small orders experienced a net outflow of 14.74 million yuan, accounting for 6.65% [1] Company Overview - Jianmin Pharmaceutical Group Co., Ltd. was established in 1993 and is located in Wuhan, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 1.533986 billion yuan and a paid-in capital of 421.12614 million yuan [2] - The legal representative of the company is Wang Jun [2] Investment and Intellectual Property - Jianmin Pharmaceutical has made investments in 30 enterprises and participated in 5,000 bidding projects [2] - The company holds 526 trademark registrations and 241 patent applications, along with 313 administrative licenses [2]